Our partners at AstraZeneca have a nice profile on their website that talks about our collaboration to create an acoustically loaded mass spec platform, and why they chose to invest in the Labcyte Echo technology. The goal of this work is to expand the utility of mass spectrometry for high-throughput, low-cost, label-free analysis. As you may recall, this product won the SLAS Innovation Award in 2015!
ARTICLE: Individualized Medicine vs. Precision Medicine - DDNews
There are people who will die of cancer this week even though there are drugs that could help them. At the same time, hundreds of patients will undergo cancer chemotherapy that, while debilitating and expensive, will not cure them of their disease.
WEBINAR: Enabling Cancer Research with Echo Acoustic Liquid Handlers: a PI3K Pathway Case Study
Class I Phosphoinositide 3-kinase (PI3K) proteins have been extensively characterized with respect to their roles in cell proliferation and tumorigenesis, and serve as highly sought-after targets for oncogenic drug development. Labcyte Sr. Applications Scientist Linda Orren will present a series of experiments, all of which target some aspect of the PI3K pathway. These case studies will highlight specifics of assay development and miniaturization that are uniquely enabled by Echo Acoustic Liquid Handlers.
Improved Cell Screening Shows Promise for Leukemia Patients
In an article recently published by In Vivo: Business & Medicine Report, author Mark Ratner writes about the growing use of high-throughput cell screening to identify combinations of therapeutics that are effective against cancer.
Acoustic Liquid Handling Is Making Personalized Medicine a Reality
Labcyte Senior Research Fellow Joe Olechno has a new article in Personalized Medicine in Oncology that offers an informative view of how the Echo® Liquid Handler based on acoustic droplet ejection technology has been instrumental in recent efforts using ex vivo cell assays to inform individualized treatment decisions.